[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 26 of about 26
1. Kaplan HG, Malmgren JA, Atwood M: Leukemia incidence following primary breast carcinoma treatment. Cancer; 2004 Oct 1;101(7):1529-36
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leukemia incidence following primary breast carcinoma treatment.
  • BACKGROUND: The results of randomized clinical trials have suggested that after receiving radiotherapy and/or chemotherapy, patients with primary breast carcinoma have an increased risk of developing leukemia.
  • In the current study, the authors set out to assess the reported association between breast carcinoma treatment and leukemia risk.
  • METHODS: A registry of all patients with breast carcinoma who were treated at a community-based institution since 1989 (updated annually for recurrence and/or vital status) was linked to the National Cancer Institute Surveillance, Epidemiology, and End Results database to confirm complete ascertainment of leukemia cases occurring within this registry population.
  • Incidence rates were calculated for women who were treated for primary Stage 0-III breast carcinoma and had a follow-up duration of > or = 24 months (n = 2866).
  • Patients who did not undergo surgery (n = 5), patients for whom chemotherapy records were incomplete or who received nonstandard chemotherapy regimens (n = 69), patients who underwent stem cell transplantation (n = 83), and patients who were lost to follow-up or who had unknown disease status at follow-up (n = 81) were excluded from the analysis (total, n = 238).
  • RESULTS: Among patients diagnosed with breast carcinoma between 1992 and 1999, the crude overall leukemia incidence rate was 0.28%, and the acute myelogenous leukemia (AML)/myelodysplastic syndrome (MDS) incidence rate was 0.11%.
  • Eight incident cases of leukemia were documented (2 cases of AML, 1 case of acute lymphoblastic leukemia, 1 case of MDS/refractory anemia with excess blasts, 2 cases of chronic myelogenous leukemia, and 2 cases of chronic lymphocytic leukemia).
  • National age-adjusted overall leukemia incidence rates for the period 1996-1998 predict the occurrence of 9 cases (incidence rate, 0.31%) in the current cohort of women ages 21-94 years.
  • The incidence of leukemia by treatment category was as follows: no surgery/no chemotherapy/no radiotherapy, 2 of 154 patients (1.30%); surgery/no chemotherapy/radiotherapy, 4 of 1403 patients (0.29%); surgery/chemotherapy/no radiotherapy, 0 of 352 patients (0%); and surgery/chemotherapy/radiotherapy, 2 of 957 patients (0.21%).
  • CONCLUSIONS: In contrast to findings reported from previous randomized clinical trials, the authors did not find evidence of increased posttreatment leukemia incidence in association with the use of chemotherapy, including doxorubicin-based regimens.
  • [MeSH-major] Breast Neoplasms / therapy. Leukemia / etiology. Neoplasms, Second Primary / etiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / epidemiology. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / etiology. Leukemia, Myeloid, Acute / epidemiology. Leukemia, Myeloid, Acute / etiology. Middle Aged. Myelodysplastic Syndromes / epidemiology. Myelodysplastic Syndromes / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 American Cancer Society.
  • [CommentIn] Cancer. 2004 Oct 1;101(7):1479-81 [15378475.001]
  • (PMID = 15378478.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


2. Bellon JR, Shulman LN, Come SE, Li X, Gelman RS, Silver BJ, Harris JR, Recht A: A prospective study of concurrent cyclophosphamide/methotrexate/5-fluorouracil and reduced-dose radiotherapy in patients with early-stage breast carcinoma. Cancer; 2004 Apr 1;100(7):1358-64
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective study of concurrent cyclophosphamide/methotrexate/5-fluorouracil and reduced-dose radiotherapy in patients with early-stage breast carcinoma.
  • BACKGROUND: Concurrent administration of chemotherapy and radiotherapy has the potential advantage of delaying neither treatment and providing radiation sensitization.
  • However, the optimal approach to concurrent treatment in women with early-stage breast carcinoma remains undefined.
  • METHODS: One hundred twelve women with AJCC Stage I or Stage II breast carcinoma with 0-3 positive axillary lymph nodes were enrolled in a prospective single-arm study of concurrent CMF and reduced-dose radiotherapy (39.6 gray [Gy] to the whole breast, 16-Gy boost).
  • One patient developed acute myelogenous leukemia.
  • An additional patient developed Grade 2 pneumonitis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / radiotherapy. Cyclophosphamide / therapeutic use. Fluorouracil / therapeutic use. Methotrexate / therapeutic use
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Prospective Studies. Radiation Dosage. Risk Factors. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 American Cancer Society.
  • (PMID = 15042668.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate; CMF regimen
  •  go-up   go-down


3. Chao NJ, Snyder DS, Jain M, Wong RM, Niland JC, Negrin RS, Long GD, Hu WW, Stockerl-Goldstein KE, Johnston LJ, Amylon MD, Tierney DK, O'Donnell MR, Nademanee AP, Parker P, Stein A, Molina A, Fung H, Kashyap A, Kohler S, Spielberger R, Krishnan A, Rodriguez R, Forman SJ, Bluzme KG: Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: results of a prospective double-blind randomized trial. Biol Blood Marrow Transplant; 2000;6(3):254-61
Hazardous Substances Data Bank. CYCLOSPORIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have previously demonstrated a decrease in the incidence of acute graft-versus-host disease (GVHD) with the addition of methotrexate (MTX) to cyclosporine (CSP) and prednisone (PSE) chemotherapy in patients with leukemia.
  • We have now completed a prospective randomized trial comparing the 3-drug regimen (CSP/MTX/PSE, including 3 doses of MTX) to the standard 2-drug regimen (CSP/MTX, including 4 doses of MTX) to investigate the benefit of PSE used up front for the prevention of acute and chronic GVHD.
  • The 2 groups were well balanced with respect to diagnosis, disease stage, age, donor-recipient sex, and parity.
  • In an intent-to-treat analysis, the incidence of acute GVHD was 18% (95% confidence interval [CI] 12-28) for the CSP/MTX/PSE group compared with 20% (CI 10-26) for the CSP/,MTX group (P = .60), with a median follow up of 2.2 years.
  • These data suggest that the addition of PSE was associated with a somewhat lower incidence of early posttransplantation complications but did not have a positive impact on the incidence of acute or chronic GVHD or event-free or overall survival.
  • [MeSH-major] Anti-Inflammatory Agents / administration & dosage. Bone Marrow Transplantation. Cyclosporine / administration & dosage. Graft vs Host Disease / prevention & control. Immunosuppressive Agents / administration & dosage. Leukemia / therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Methotrexate / administration & dosage. Prednisone / administration & dosage
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Child. Child, Preschool. Double-Blind Method. Humans. Infant. Middle Aged. Prospective Studies. Survival Analysis. Transplantation, Homologous. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Steroids.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10871150.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


Advertisement
4. Kim SG, Chun JM, Jin R, Kim JY, Won DI, Hwang YJ: Living donor liver transplantation for acute hepatic failure caused by reactivation of hepatitis B virus infection after chemotherapy for hematologic malignancy: case reports. Transplant Proc; 2010 Apr;42(3):843-5
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Living donor liver transplantation for acute hepatic failure caused by reactivation of hepatitis B virus infection after chemotherapy for hematologic malignancy: case reports.
  • Cancer chemotherapy in chronic hepatitis B virus (HBV) carriers occasionally leads to acute hepatic failure (AHF) from viral reactivation resulting in an high mortality rate.
  • Herein we have reported 2 cases of successful LDLT performed for AHF caused by reactivation of HBV infection during chemotherapy for hematologic malignancies.
  • During 4 cycles of chemotherapy he developed right upper quadrant pain and jaundice.
  • Laboratory data (alanine amino transferase, 701 U/L, total bilirubin: 7.92 mg/dL, positive hepatitis B e antigen showed that he had experienced an acute exacerbation of chronic hepatitis.
  • Soon, he developed grade IV hepatic encephalopathy with a total bilirubin level of 50.56 mg/dL and a model for End-Stage Liver Disease score of 40.
  • In case 2, a 49-year-old male HBV carrier was diagnosed in the chronic phase of chronic myeloid leukemia.
  • The patient had been under Imatinib treatment for 1 year until he was admitted for AHF.
  • He developed grade II encephalopathy with a total bilirubin of 50.8 mg/dL.
  • LDLT was a life-saving procedure for AHF caused by reactivation of HBV during chemotherapy for hematologic malignancy.
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Benzamides. Carrier State. Disease-Free Survival. Humans. Imatinib Mesylate. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Living Donors. Male. Middle Aged. Piperazines / therapeutic use. Pyrimidines / therapeutic use. Recurrence. Treatment Outcome

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20430187.001).
  • [ISSN] 1873-2623
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


5. Venturini M, Del Mastro L, Aitini E, Baldini E, Caroti C, Contu A, Testore F, Brema F, Pronzato P, Cavazzini G, Sertoli MR, Canavese G, Rosso R, Bruzzi P: Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial. J Natl Cancer Inst; 2005 Dec 7;97(23):1724-33
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial.
  • METHODS: A total of 1214 patients with early-stage breast cancer were randomly assigned to receive six cycles of FEC14 (604 patients) or of FEC21 (610 patients).
  • RESULTS: Patients in the FEC14 arm had fewer dose reductions or treatment delays or discontinuation (26%) than those in the FEC21 arm (33%) (difference = 7%, 95% confidence interval [CI] = 2% to 12%; P = .008).
  • FEC14 therapy, compared with FEC21 therapy, was associated with more asthenia (36% versus 29%, difference = 7%, 95% CI = 2% to 12%; P = .01), bone pain (33% versus 4%, difference = 29%, 95% CI = 25% to 33%; P < .001), anemia (38% versus 19%, difference = 19%, 95% CI = 14% to 24%; P < .001), and thrombocytopenia (8% versus 2%, difference = 6%, 95% CI = 4% to 9%; P < .001), but with less leukopenia (12% versus 45%, difference = 33%, 95% CI = 28% to 37%; P < .001).
  • No acute myelogenous leukemia or myelodysplastic syndrome was observed.
  • Although the study was underpowered for subset analysis, we found no evidence that the effect of the treatment type was associated with any of the potential prognostic factors.
  • CONCLUSION: Our results support the long-term safety of FEC14 chemotherapy as an adjuvant treatment of breast cancer.
  • However, this therapy was not associated with improved outcome, but because of the limited statistical power of our study, we cannot rule out a modest improvement in outcome associated with FEC14 therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Breast Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Confidence Intervals. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Disease-Free Survival. Dose-Response Relationship, Drug. Drug Administration Schedule. Epirubicin / administration & dosage. Epirubicin / adverse effects. Female. Filgrastim. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Infusions, Intravenous. Italy. Middle Aged. Multivariate Analysis. Odds Ratio. Recombinant Proteins. Risk Factors. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Filgrastim .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Cancer Inst. 2005 Dec 7;97(23):1712-4 [16333021.001]
  • (PMID = 16333028.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 3Z8479ZZ5X / Epirubicin; 8N3DW7272P / Cyclophosphamide; PVI5M0M1GW / Filgrastim; U3P01618RT / Fluorouracil; FEC protocol
  •  go-up   go-down


6. Weisberg E, Manley P, Mestan J, Cowan-Jacob S, Ray A, Griffin JD: AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer; 2006 Jun 19;94(12):1765-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chronic myelogenous leukaemia (CML) and Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) are caused by the BCR-ABL oncogene.
  • Imatinib inhibits the tyrosine kinase activity of the BCR-ABL protein and is an effective, frontline therapy for chronic-phase CML.
  • However, accelerated or blast-crisis phase CML patients and Ph+ ALL patients often relapse due to drug resistance resulting from the emergence of imatinib-resistant point mutations within the BCR-ABL tyrosine kinase domain.
  • In addition to being more potent than imatinib (IC50< 30 nM) against wild-type BCR-ABL, AMN107 is also significantly active against 32/33 imatinib-resistant BCR-ABL mutants.
  • In preclinical studies, AMN107 demonstrated activity in vitro and in vivo against wild-type and imatinib-resistant BCR-ABL-expressing cells.
  • In phase I/II clinical trials, AMN107 has produced haematological and cytogenetic responses in CML patients, who either did not initially respond to imatinib or developed imatinib resistance.
  • Future trends investigating prediction of mechanisms of resistance to AMN107, and how and where AMN107 is expected to fit into the overall picture for treatment of early-phase CML and imatinib-refractory and late-stage disease are discussed.
  • [MeSH-major] Antineoplastic Agents. Genes, abl / drug effects. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Pyrimidines

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 1984 Jan;36(1):93-9 [6319012.001]
  • [Cites] Blood. 2007 Jun 1;109(11):5011-5 [17303698.001]
  • [Cites] J Clin Oncol. 1988 Jan;6(1):180-2 [3422090.001]
  • [Cites] Science. 1990 Mar 2;247(4946):1079-82 [2408149.001]
  • [Cites] Nat Med. 1996 May;2(5):561-6 [8616716.001]
  • [Cites] Cancer Cell. 2005 Feb;7(2):129-41 [15710326.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4500-5 [15930265.001]
  • [Cites] Clin Cancer Res. 2005 Jul 1;11(13):4941-7 [16000593.001]
  • [Cites] Science. 2000 Sep 15;289(5486):1938-42 [10988075.001]
  • [Cites] J Pharmacol Exp Ther. 2000 Oct;295(1):139-45 [10991971.001]
  • [Cites] Science. 2001 Aug 3;293(5531):876-80 [11423618.001]
  • [Cites] Blood. 2002 May 15;99(10):3530-9 [11986204.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4236-43 [12154025.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1965-71 [12200353.001]
  • [Cites] N Engl J Med. 2003 Oct 9;349(15):1423-32 [14534335.001]
  • [Cites] Bioorg Med Chem Lett. 2004 Dec 6;14(23):5793-7 [15501042.001]
  • [Cites] Nature. 1983 Nov 17-23;306(5940):277-80 [6580527.001]
  • [Cites] Leukemia. 2005 Sep;19(9):1670-1 [16015383.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9436-44 [16230407.001]
  • [Cites] Blood. 2005 Nov 1;106(9):3206-13 [16030188.001]
  • [Cites] Blood. 2006 Jan 15;107(2):752-9 [16189265.001]
  • [Cites] Blood. 2006 Jul 15;108(2):697-704 [16597591.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1328-33 [16614241.001]
  • [Cites] Nature. 1987 Feb 12-18;325(6105):635-7 [3027581.001]
  • (PMID = 16721371.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide; 0 / Antineoplastic Agents; 0 / Pyrimidines
  • [Number-of-references] 30
  • [Other-IDs] NLM/ PMC2361347
  •  go-up   go-down


7. Parikh SH, Mendizabal A, Martin PL, Prasad VK, Szabolcs P, Driscoll TA, Kurtzberg J: Unrelated donor umbilical cord blood transplantation in pediatric myelodysplastic syndrome: a single-center experience. Biol Blood Marrow Transplant; 2009 Aug;15(8):948-55
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Myelodysplastic syndromes (MDS) respond poorly to chemotherapy.
  • The median age was 11.1 years (range: 1.1-19.7), median weight was 38.6 kg (range: 9.6-62.6), 61% of patients were male, and median time from diagnosis to transplant was 6.6 months (range: 2.0-61.4).
  • MDS stage was refractory anemia (RA) in 12, refractory anemia with excess blasts (RAEB) in 8, and refractory anemia with excess blasts in transformation (RAEB-T) in 3 patients; 18 (78%) patients had primary MDS.
  • Patients with acute myelogenous leukemia (AML) were excluded.
  • Three patients developed acute GVHD (aGVHD) grades II-IV with a cumulative incidence at 100 days of 13% (95% CI 0.0%-27.1.0%).
  • UUCB should be actively considered for pediatric MDS patients lacking matched related or unrelated adult donors.
  • [MeSH-major] Cord Blood Stem Cell Transplantation / methods. Myelodysplastic Syndromes / therapy
  • [MeSH-minor] Adolescent. Adult. Anemia, Refractory, with Excess of Blasts. Chemoprevention / methods. Child. Female. Graft vs Host Disease / drug therapy. Graft vs Host Disease / prevention & control. Humans. Male. Middle Aged. Retrospective Studies. Survival Analysis. Tissue Donors. Treatment Outcome. Whole-Body Irradiation. Young Adult


8. Rizzieri DA, Feldman E, Dipersio JF, Gabrail N, Stock W, Strair R, Rivera VM, Albitar M, Bedrosian CL, Giles FJ: A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res; 2008 May 1;14(9):2756-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A Simon two-stage design was used for each cohort.
  • RESULTS: Fifty-five patients received deforolimus as follows: cohort 1 23 acute myelogenous leukemia, two myelodysplastic syndrome and one chronic myelogenous leukemia in nonlymphoid blast phase; cohort 2, one acute lymphocytic leukemia; cohort 3, nine agnogenic myeloid metaplasia; cohort 4, eight chronic lymphocytic leukemia; cohort 5, nine mantle cell lymphoma and two T-cell leukemia/lymphoma.
  • Of the 52 evaluable patients, partial responses were noted in five (10%), two of seven agnogenic myeloid metaplasia and three of nine mantle cell lymphoma.
  • Common treatment-related adverse events, which were generally mild and reversible, were mouth sores, fatigue, nausea, and thrombocytopenia.
  • Decreased levels of phosphorylated 4E-BP1 in 9 of 11 acute myelogenous leukemia/myelodysplastic syndrome patients after therapy showed mammalian target of rapamycin inhibition by deforolimus.
  • Further investigation of deforolimus alone and in combination with other therapeutic agents is warranted in patients with selected hematologic malignancies.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Hematologic Neoplasms / drug therapy. Sirolimus / analogs & derivatives. Vascular Endothelial Growth Factor A / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cohort Studies. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18451242.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 48Z35KB15K / ridaforolimus; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


9. Rosenthal SA, Bae K, Pienta KJ, Sobczak ML, Asbell SO, Rajan R, Kerlin KJ, Michalski JM, Sandler HM, Radiation Therapy Oncology Group Trial 9902: Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02. Int J Radiat Oncol Biol Phys; 2009 Mar 1;73(3):672-8
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02.
  • PURPOSE: Long-term androgen suppression plus radiotherapy (AS+RT) is standard treatment of high-risk prostate cancer.
  • A randomized trial, Radiation Therapy Oncology Group trial 9902, was undertaken to determine whether adjuvant chemotherapy with paclitaxel, estramustine, and etoposide (TEE) plus AS+RT would improve disease outcomes with acceptable toxicity.
  • METHODS AND MATERIALS: High-risk (prostate-specific antigen 20-100 ng/mL and Gleason score >or=7; or Stage T2 or greater, Gleason score 8, prostate-specific antigen level <100 ng/mL) nonmetastatic prostate cancer patients were randomized to AS+RT (Arm 1) vs. AS+RT plus four cycles of TEE (Arm 2).
  • AS continued for 2 years for both treatment arms.
  • RESULTS: The Radiation Therapy Oncology Group 9902 trial opened January 11, 2000.
  • An acute and long-term toxicity analysis was performed.
  • The worst overall toxicities during treatment were increased for Arm 2.
  • Statistically significant increases in hematologic toxicity (p < 0.0001) and gastrointestinal toxicity (p = 0.017) but not genitourinary toxicity (p = 0.07) were noted during treatment.
  • Three cases of myelodysplasia/acute myelogenous leukemia were noted in Arm 2.
  • At 2 and 3 years after therapy completion, excess long-term toxicity was not observed in Arm 2.
  • CONCLUSION: TEE was associated with significantly increased toxicity during treatment.
  • The toxicity profiles did not differ at 2 and 3 years after therapy.
  • Toxicity is an important consideration in the design of trials using adjuvant chemotherapy for prostate cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Prostatic Neoplasms / drug therapy. Thromboembolism / chemically induced
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Androgen Antagonists / administration & dosage. Androgen Antagonists / adverse effects. Chemotherapy, Adjuvant / adverse effects. Combined Modality Therapy / adverse effects. Drug Administration Schedule. Estramustine / administration & dosage. Estramustine / adverse effects. Etoposide / administration & dosage. Etoposide / adverse effects. Follow-Up Studies. Humans. Leukemia, Myeloid, Acute / chemically induced. Male. Middle Aged. Myelodysplastic Syndromes / chemically induced. Paclitaxel / administration & dosage. Paclitaxel / adverse effects

  • Genetic Alliance. consumer health - Oral cancer.
  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18990504.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10 CA21661; United States / NCI NIH HHS / CA / U10 CA32115; United States / NCI NIH HHS / CA / U10 CA37422
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgen Antagonists; 35LT29625A / Estramustine; 6PLQ3CP4P3 / Etoposide; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


10. Tanaka H, Imamura N, Oguma N, Shintani T, Tanaka K, Hyodo H, Oda K, Kimura A: Acute myelogenous leukemia with PIG-A gene mutation evolved from aplastic anemia-paroxysmal nocturnal hemoglobinuria syndrome. Int J Hematol; 2001 Feb;73(2):206-12
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myelogenous leukemia with PIG-A gene mutation evolved from aplastic anemia-paroxysmal nocturnal hemoglobinuria syndrome.
  • We report a patient with aplastic anemia (AA)-paroxysmal nocturnal hemoglobinuria (PNH) syndrome who developed acute myelogenous leukemia (AML).
  • Heteroduplex and single-strand conformation polymorphism analysis followed by sequencing of the leukemic cells in the bone marrow disclosed 1 frameshift-type mutation in exon 2 of the phosphatidylinositol glycan-class A (PIG-A) gene, which deductively produces truncated PIG-A protein.
  • Cytogenetic analysis in the bone marrow in each stage of AA-PNH, AML, and at relapse of AML showed normal, -7, and -7 plus -20, respectively, showing evidence of a clonal evolution.
  • Because complete remission of AML was not achieved by intensive chemotherapies, allogeneic peripheral blood stem cell transplantation (PBSCT) from the patient's HLA-matched sister was performed successfully with recovery of CD59 antigen on bone marrow hematopoietic cells; however, leukemia relapsed 4 months after PBSCT.
  • Leukemia derived from PNH may be resistant to intensive chemotherapy, and a highly myeloablative regimen may be required for stem cell transplantation to eradicate the PNH-derived leukemia clone.
  • [MeSH-major] Anemia, Aplastic / pathology. Hemoglobinuria, Paroxysmal / pathology. Leukemia, Myeloid, Acute / genetics. Membrane Proteins / genetics
  • [MeSH-minor] Adult. Antigens, CD59 / analysis. Bone Marrow / pathology. Cytogenetic Analysis. Female. Frameshift Mutation. Humans. Immunophenotyping. P-Glycoprotein / metabolism


11. Ferrá C, Berlanga JJ, Gallardo D, Ancín I, Marín D, González JR, Peris J, Muñoz J, Sarrá J, Grañena A: Mitoxantrone, etoposide, carboplatinum and ara-C combination therapy (MECA) in refractory and relapsed acute leukemia. Leuk Lymphoma; 2000 Nov;39(5-6):583-90
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mitoxantrone, etoposide, carboplatinum and ara-C combination therapy (MECA) in refractory and relapsed acute leukemia.
  • The present study was undertaken to assess the feasibility, toxicity and antileukemic activity of sequential chemotherapy including mitoxantrone, etoposide, carboplatin and intermediate-dose cytarabine in adult patients with refractory and relapsed acute myelogenous (AML) or lymphoid (ALL) leukemia.
  • Fifty-one patients with poor-risk AML and ALL received 64 courses of MECA therapy.
  • The stage of the disease (relapsed or primarily refractory) and the age of the patients did not strongly affect the response rate.
  • MECA therapy was more effective in ALL than in AML, and in those patients who presented at salvage treatment with a bone marrow infiltration lower than 25% blasts.
  • Hematological and extra-hematological toxicities were tolerable and there were 6 deaths related to the treatment (11%).
  • MECA therapy is a safe treatment and has a high antileukemic activity in relapsed and primarily refractory AML or ALL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia / drug therapy
  • [MeSH-minor] Actuarial Analysis. Acute Disease. Adolescent. Adult. Carboplatin / administration & dosage. Carboplatin / toxicity. Cytarabine / administration & dosage. Cytarabine / toxicity. Disease-Free Survival. Etoposide / administration & dosage. Etoposide / toxicity. Female. Hematopoietic Stem Cell Transplantation. Humans. Male. Middle Aged. Mitoxantrone / administration & dosage. Mitoxantrone / toxicity. Recurrence. Risk Factors. Salvage Therapy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11342341.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; BZ114NVM5P / Mitoxantrone; MECA protocol
  •  go-up   go-down


12. Espérou H, Boiron JM, Cayuela JM, Blanchet O, Kuentz M, Jouet JP, Milpied N, Cahn JY, Faucher C, Bourhis JH, Michallet M, Tanguy ML, Vernant JP, Gabert J, Bordigoni P, Ifrah N, Baruchel A, Dombret H, French Bone Marrow Transplantation: A potential graft-versus-leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: results from the French Bone Marrow Transplantation Society. Bone Marrow Transplant; 2003 May;31(10):909-18
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A potential graft-versus-leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: results from the French Bone Marrow Transplantation Society.
  • SUMMARY: Philadelphia chromosome (Ph) acute lymphoblastic leukemia-positive (ALL) is a subgroup of ALL with a poor prognosis.
  • From 1992 to 2000, 121 patients with Ph- positive ALL enrolled in one of the three main French prospective ALL chemotherapy trials and receiving allogeneic HSCT were reported to the registry of the French Society of Bone Marrow Transplantation (SFGM-TC).
  • In all, 76 patients received HSCT in first complete remission and 45 in a more advanced disease stage.
  • Relapse was the most common cause of treatment failure.
  • Hematological status at the time of transplant and the occurrence of acute graft-versus-host disease (GvHD) were the only two prognostic factors identified for relapse (P=0.02 and 0.02, respectively).
  • Detection of BCR-ABL transcripts after transplantation had a predictive value on relapse occurrence.
  • The graft-versus-leukemia effect of HSCT in Ph-positive ALL appears to be supported by (1) the lack of prognostic significance of pretransplant BCR-ABL transcript detection, (2) the efficacy of donor lymphocyte infusions in cases of relapse, and (3) the role of GvHD as protecting against relapse.
  • [MeSH-major] Graft vs Leukemia Effect / immunology. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Stem Cell Transplantation / adverse effects. Transplantation, Homologous / immunology
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Transplantation. Child. Child, Preschool. Chronic Disease. Female. Follow-Up Studies. Graft vs Host Disease / epidemiology. Humans. Infant. Male. Middle Aged. Neoplasm, Residual / epidemiology. Societies, Medical. Survival Rate. Time Factors. Tissue Donors / statistics & numerical data. Treatment Outcome


13. Yujiri T, Sato Y, Tanizawa Y: Sustained cytogenetic remission induced by imatinib mesylate in a chronic myeloid leukemia patient who had a relapse into lymphoid crisis after allogeneic hematopoietic stem cell transplantation. Int J Hematol; 2004 Jul;80(1):67-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sustained cytogenetic remission induced by imatinib mesylate in a chronic myeloid leukemia patient who had a relapse into lymphoid crisis after allogeneic hematopoietic stem cell transplantation.
  • We report on the response to imatinib mesylate in a chronic myeloid leukemia patient who, after undergoing allogeneic hematopoietic stem cell transplantation (alloHSCT) for treatment of lymphoid blastic crisis, had a relapse into blastic crisis despite the presence of chronic and grade II acute graft-versus-host disease (GVHD).
  • Complete hematologic response and the disappearance of the Bcr-Abl fusion signal on fluorescence in situ hybridization analysis were achieved after 10 weeks of imatinib therapy and were maintained for 26 months with no adverse effects, including recurrence of GVHD.
  • This case highlights the ability of imatinib to induce sustained hematologic and cytogenetic remission in some patients who have had relapses into advanced-stage chronic myeloid leukemia after alloHSCT.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Blast Crisis / drug therapy. Hematopoietic Stem Cell Transplantation / adverse effects. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Piperazines / administration & dosage. Pyrimidines / administration & dosage
  • [MeSH-minor] Adult. Benzamides. Female. Genes, abl / genetics. Graft vs Host Disease / complications. Humans. Imatinib Mesylate. In Situ Hybridization, Fluorescence. Recurrence. Remission Induction. Transplantation Chimera. Transplantation, Homologous


14. Deutsch M, Jacobs SA: Kaposi sarcoma after treatment of Hodgkin's disease in a young adult non-AIDS patient: case report and review. Am J Clin Oncol; 2000 Feb;23(1):26-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kaposi sarcoma after treatment of Hodgkin's disease in a young adult non-AIDS patient: case report and review.
  • We describe a young woman diagnosed with Hodgkin's disease, stage I, at age 20 years.
  • She delayed treatment until age 23, at which time she was considered to have stage II-A disease and was then treated with chemotherapy and involved field irradiation.
  • Two years later, Kaposi sarcoma, which developed on her right shoulder, was excised.
  • Both the Hodgkin's disease and Kaposi sarcoma appeared to be cured, but 3 years later, acute myelogenous leukemia developed and the patient subsequently died in relapse.
  • This is one of the very few instances of a young patient, not infected with the AIDS virus, in whom Kaposi sarcoma developed as a second malignancy after treatment of Hodgkin's disease.
  • [MeSH-major] Hodgkin Disease. Leukemia, Myeloid, Acute / etiology. Neoplasms, Second Primary / etiology. Sarcoma, Kaposi / etiology
  • [MeSH-minor] Adult. Combined Modality Therapy. Fatal Outcome. Female. HIV Seronegativity. Humans


15. Erba HP, Kantarjian HM, Claxton DF, Arellano M, Lyons RM, Kovacsovics TJ, Gabrilove J, Eckert S, Faderl S: Updated remission duration and survival results of single-agent clofarabine in previously untreated older adult patients with acute myelogenous leukemia (AML) unlikely to benefit from standard induction chemotherapy due to unfavorable baseline risk factor(s). J Clin Oncol; 2009 May 20;27(15_suppl):7062

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Updated remission duration and survival results of single-agent clofarabine in previously untreated older adult patients with acute myelogenous leukemia (AML) unlikely to benefit from standard induction chemotherapy due to unfavorable baseline risk factor(s).
  • METHODS: Single arm, multi-center, phase II, open-label, 2-stage study of patients with untreated AML, ≥60 years old, and at least one adverse prognostic factor: age ≥70 years, antecedent hematologic disorder (AHD), PS = 2, and/or intermediate/unfavorable risk karyotype.
  • Median DOR (censored at alternative therapy) for CR/CRp was 56 weeks (95% CI, 33 weeks - not yet estimable [n/e]) and for CR 65 weeks (95% CI, 41 weeks - n/e).
  • Median DFS (not censored at alternative therapy) for CR/CRp was 34 weeks (95% CI, 24 - 65 weeks).
  • CONCLUSIONS: These data expand on the previously reported efficacy and safety data of single agent CLO in adult AML.
  • These results suggest that single agent CLO is an effective and tolerable treatment option for older adult patients with untreated AML and 1 or more unfavorable baseline prognostic factor(s).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961436.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Chaidos A, Kanfer E, Apperley JF: Risk assessment in haemotopoietic stem cell transplantation: disease and disease stage. Best Pract Res Clin Haematol; 2007 Jun;20(2):125-54
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk assessment in haemotopoietic stem cell transplantation: disease and disease stage.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Neoplasms / therapy
  • [MeSH-minor] Acute Disease. Adult. Benzamides. Female. Humans. Imatinib Mesylate. Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Leukemia, Myeloid / therapy. Male. Multiple Myeloma / therapy. Myelodysplastic Syndromes / therapy. Neoplasm Staging. Piperazines / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Prognosis. Pyrimidines / therapeutic use. Recurrence. Risk Assessment. Survival Analysis. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17448953.001).
  • [ISSN] 1521-6926
  • [Journal-full-title] Best practice & research. Clinical haematology
  • [ISO-abbreviation] Best Pract Res Clin Haematol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  • [Number-of-references] 154
  •  go-up   go-down


17. Fischer T: [Results up to now of administration of STI-571 (Glivec) in recurrence after allogenic and autologous stem cell transplantation in chronic myeloid leukemia]. Med Klin (Munich); 2002 Jan 15;97 Suppl 1:22-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Results up to now of administration of STI-571 (Glivec) in recurrence after allogenic and autologous stem cell transplantation in chronic myeloid leukemia].
  • THERAPY AND RESULTS: 18 of 18 patients with cytogenetic and/or hematologic relapse in chronic phase CML post autologous stem cell transplantation achieved a complete hematologic remission upon therapy with Gleevec.
  • After allogeneic stem cell transplantation, patients in cytogenetic or hematologic relapse also experienced high hematologic and cytogenetic response rates upon therapy with Gleevec.
  • No symptoms of chronic extensive or > grade I acute GvHD could be observed.
  • Hematologic toxicity was dependent on stage of disease.
  • CONCLUSION: These results show a new approach in treatment of patients with Philadelphia-chromosome-positive leukemia relapsing post autologous or allogeneic stem cell transplantation.
  • The data suggest that early start of STI-571 therapy in MRD-positive patients is a promising approach.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Enzyme Inhibitors / therapeutic use. Hematopoietic Stem Cell Transplantation. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Benzamides. Child. Clinical Trials as Topic. Female. Humans. Imatinib Mesylate. Male. Middle Aged. Remission Induction. Treatment Outcome


18. Wang S, Nademanee A, Qian D, Dagis A, Park HS, Fridey J, Smith E, Snyder D, Somlo G, Stein A, Rosenthal J, Falk P, Kogut N, Palmer J, Gaal K, Kim Y, Bhatia R, Yuan S, Kay C, Weiss L, Forman S: Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation. Transfusion; 2007 Dec;47(12):2207-16
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The successful mobilization and collection of hematopoietic stem cells are dependent on a number of clinical factors such as previous chemotherapy and disease stage.
  • STUDY DESIGN AND METHODS: A total of 358 patients who received transplants from January 2003 to December 2004 (201 male and 157 female patients, ages from 2.7 to 77.3 years with median of 53 years of age) underwent autologous hematopoietic stem cell collection after mobilization with granulocyte-colony-stimulating factor (G-CSF) or G-CSF plus chemotherapy priming.
  • This retrospective study included patients with diagnoses of acute myelogenous leukemia, non-Hodgkin's lymphoma, Hodgkin's disease, multiple myeloma, and solid tumors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Mobilization / methods. Peripheral Blood Stem Cell Transplantation / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD34 / analysis. Child. Child, Preschool. Combined Modality Therapy. Female. Granulocyte Colony-Stimulating Factor / pharmacology. Hodgkin Disease / metabolism. Hodgkin Disease / therapy. Humans. Lymphoma, Non-Hodgkin / metabolism. Lymphoma, Non-Hodgkin / therapy. Male. Middle Aged. Multiple Myeloma / metabolism. Multiple Myeloma / therapy. Prognosis. Retrospective Studies. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17714420.001).
  • [ISSN] 0041-1132
  • [Journal-full-title] Transfusion
  • [ISO-abbreviation] Transfusion
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA30206; United States / NCI NIH HHS / CA / P30 CA33572
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


19. Perseghin P, Terruzzi E, Dassi M, Baldini V, Parma M, Coluccia P, Accorsi P, Confalonieri G, Tavecchia L, Verga L, Ravagnani F, Iacone A, Pogliani EM, Pioltelli P: Management of poor peripheral blood stem cell mobilization: incidence, predictive factors, alternative strategies and outcome. A retrospective analysis on 2177 patients from three major Italian institutions. Transfus Apher Sci; 2009 Aug;41(1):33-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CD34+ peripheral blood hematopoietic stem cells (HSC) are usually collected following mobilization therapy accomplished by using growth factors (GF) such as rHuG-CSF or rHuGM-CSF with or without chemotherapy.
  • In fact, 5-46% of patients who underwent mobilization therapy fail HSC collection due to very low peripheral blood HSC CD34+ count.
  • Patients' characteristics, including age, sex, stage of the underlying disease (complete or partial remission), diagnosis, previously administered radio/chemotherapy regimens, time-lapse from last chemotherapy before mobilization and mobilization schedule (including dose of GF) were considered as possibly predictive of poor or failed mobilization.
  • Therefore, a patient who fails a first mobilization (and when an HLA-compatible related on unrelated donor is not available) could undergo a second attempt either with different mobilization schedule or by using different GF, such as stem cell factor, growth hormone (GH), or more recently newly introduced drugs such as AMD3100, alone or in combination with rHuG- or -rHuGM-CSF.
  • Thus, we investigated the fate of those who failed a first mobilization and subsequently underwent a second attempt or alternative therapeutic approaches.
  • [MeSH-minor] Adult. Antigens, CD34 / blood. Follow-Up Studies. Hematopoiesis. Hematopoietic Stem Cell Mobilization / methods. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / surgery. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / surgery. Leukemia, Myeloid, Acute / surgery. Lymphoma, Non-Hodgkin / surgery. Multiple Myeloma / surgery. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19540167.001).
  • [ISSN] 1473-0502
  • [Journal-full-title] Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • [ISO-abbreviation] Transfus. Apher. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD34
  •  go-up   go-down


20. Tabata M, Satake A, Okura N, Yamazaki Y, Toda A, Nishioka K, Tanaka H, Chin M, Itsukuma T, Yamaguchi M, Misawa M, Kai S, Hara H: Long-term outcome after allogeneic bone marrow transplantation for hematological malignancies with non-remission status. Results of a single-center study of 24 patients. Ann Hematol; 2002 Oct;81(10):582-7
MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To investigate the problem of allogeneic bone marrow transplantation (allo-BMT) for advanced stage patients, we retrospectively analyzed 24 consecutive patients who underwent allo-BMT in the non-remission stage.
  • Twenty-four patients (19 males and 5 females) with acute leukemia, chronic myelogenous leukemia, and malignant lymphoma underwent allo-BMT.
  • There were eight cases of acute myelogenous leukemia (AML), six cases acute lymphocytic leukemia (ALL), nine cases of chronic myelogenous leukemia (CML), and one case of Burkitt's lymphoma.
  • The 3-year overall survival rate was 22.5%, with a median survival time of 206 days in AML, 345 days in ALL, and 363 days in CML.
  • Overall survival was associated with a recovery of platelets of less than 30 days and an acute graft-versus-host disease (acute GVHD) presence of less than grade II ( p=0.042).
  • Our important problem is to decrease transplantation-related deaths in allo-BMT during the non-remission stage, and longer survival can be expected with better pretreatment and prophylaxis for GVHD.
  • In addition, the selection of the source of hematopoietic stem cell transplantation at an optimal time is considered to be another problem to be approached.
  • [MeSH-major] Bone Marrow Transplantation. Drug Resistance, Neoplasm. Hematologic Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Cause of Death. Female. Graft vs Host Disease / diagnosis. Graft vs Host Disease / mortality. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Analysis. Survival Rate. Transplantation Conditioning. Transplantation, Homologous / adverse effects. Transplantation, Homologous / mortality. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12424540.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


21. Baron F, Gothot A, Salmon JP, Hermanne JP, Pierard GE, Fillet G, Beguin Y: Clinical course and predictive factors for cyclosporin-induced autologous graft-versus-host disease after autologous haematopoietic stem cell transplantation. Br J Haematol; 2000 Dec;111(3):745-53
Hazardous Substances Data Bank. CYCLOSPORIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thirty-three percent of the patients developed clinical GVHD: clinical stage 1 in 21 patients, stage 2 in seven patients, and stage 3 in three patients.
  • Autologous GVHD was significantly more frequent in patients older than 33 years, in patients who had received high doses of granulocyte-macrophage colony forming units (CFU-GM) and in those with a diagnosis of myeloid malignancy, compared with those with lymphoid malignancies or solid tumours.
  • [MeSH-major] Cyclosporine / therapeutic use. Graft vs Leukemia Effect / immunology. Hematopoietic Stem Cell Transplantation. Immunosuppressive Agents / therapeutic use. Leukemia / surgery. Lymphoma / surgery
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Age Factors. Aged. Breast Neoplasms / drug therapy. Breast Neoplasms / immunology. Breast Neoplasms / surgery. Chi-Square Distribution. Child. Child, Preschool. Disease-Free Survival. Female. Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use. HLA-B Antigens / immunology. HLA-DR6 Antigen / immunology. Hodgkin Disease / drug therapy. Hodgkin Disease / immunology. Hodgkin Disease / surgery. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / immunology. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / surgery. Leukemia, Myeloid / drug therapy. Leukemia, Myeloid / immunology. Leukemia, Myeloid / surgery. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / immunology. Lymphoma, Non-Hodgkin / surgery. Male. Middle Aged. Multiple Myeloma / drug therapy. Multiple Myeloma / immunology. Multiple Myeloma / surgery. Myelodysplastic Syndromes / drug therapy. Myelodysplastic Syndromes / immunology. Myelodysplastic Syndromes / surgery. Prospective Studies. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11122133.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / HLA-B Antigens; 0 / HLA-B16 antigen; 0 / HLA-DR6 Antigen; 0 / Immunosuppressive Agents; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; 83HN0GTJ6D / Cyclosporine
  •  go-up   go-down


22. Hainsworth JD, Kalman L, Castine M, Sylvester L, Greco FA: Paclitaxel, carboplatin, and oral etoposide as initial treatment for advanced ovarian carcinoma: a Minnie Pearl Cancer Research Network phase II trial. Gynecol Oncol; 2005 Apr;97(1):200-5
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel, carboplatin, and oral etoposide as initial treatment for advanced ovarian carcinoma: a Minnie Pearl Cancer Research Network phase II trial.
  • PURPOSE: To evaluate the feasibility and toxicity of the combination of paclitaxel, carboplatin, and etoposide in the first-line treatment of patients with stage III or IV adenocarcinoma of the ovary.
  • Patients received 6 courses of treatment, administered at 21-day intervals.
  • Treatment-related myelosuppression was common, but myelosuppression-related complications were uncommon, as was grade 3/4 non-hematologic toxicity.
  • No episodes of acute myelogenous leukemia have developed.
  • Unlike previous reports, no episodes of acute leukemia were seen following this treatment.
  • Definitive conclusions regarding the benefit of adding etoposide to a taxane/platinum combination will require a comparative trial.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Adult. Aged. Aged, 80 and over. Carboplatin / administration & dosage. Carboplatin / adverse effects. Disease-Free Survival. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Humans. Infusions, Intravenous. Middle Aged. Paclitaxel / administration & dosage. Paclitaxel / adverse effects

  • Genetic Alliance. consumer health - Oral cancer.
  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15790459.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


23. Hosoya Y, Lefor A, Hirashima Y, Nokubi M, Yamaguti T, Jinbu Y, Muroi K, Nakazawa M, Yasuda Y: Successful treatment of esophageal squamous cell carcinoma in a patient with Fanconi anemia. Jpn J Clin Oncol; 2010 Aug;40(8):805-10
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of esophageal squamous cell carcinoma in a patient with Fanconi anemia.
  • Fanconi anemia is a congenital syndrome characterized by hypoplasia of bone marrow and the development of aplastic anemia in childhood, followed by myelodysplastic syndrome and acute myelogenous leukemia in later life.
  • Esophageal cancer developed at age 35.
  • Invasion of the bronchus and aorta by the tumor was suspected on computed tomography.
  • Chemoradiotherapy was administered to down-stage the tumor, using low-dose cisplatin and 5-fluorouracil.
  • After two courses of chemotherapy with cisplatin (total dose, 100 mg) and 5-fluorouracil (5000 mg) plus radiotherapy (30 Gy), Grade 3 diarrhea and bone marrow suppression developed, and treatment was discontinued.
  • After resolution of toxicity, a good response to the neoadjuvant therapy was seen on computed tomography scan, and a subtotal esophagectomy was performed which demonstrated a complete response in the resected specimen.
  • However, tongue cancer developed at age 40 years, and hemiglossectomy was performed.
  • However, the optimal dosage of chemoradiotherapy and the treatment strategy for esophageal cancer in patients with Fanconi anemia remain unclear, and outcomes are generally extremely poor.
  • In this patient, esophageal cancer associated with Fanconi anemia responded well to multidisciplinary therapy.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Esophageal Neoplasms / therapy. Fanconi Anemia / complications
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Bone Marrow Transplantation. Child. Cisplatin / administration & dosage. Combined Modality Therapy. Esophagectomy. Female. Fluorouracil / administration & dosage. Humans. Neoplasm Staging. Radiotherapy Dosage. Tomography, X-Ray Computed. Tongue Neoplasms / pathology. Tongue Neoplasms / secondary


24. Huff CA, Fuchs EJ, Noga SJ, O'Donnell PV, Ambinder RF, Diehl L, Borrello I, Vogelsang GB, Miller CB, Flinn IA, Brodsky RA, Marcellus D, Jones RJ: Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells. Biol Blood Marrow Transplant; 2003 May;9(5):312-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In an endeavor to reduce procedure-related toxicity, this study retrospectively evaluated the safety, tolerability, and efficacy of T cell depletion by counterflow centrifugal elutriation before alloBMT.
  • Fifty-one patients with stage II (6) or III (45) multiple myeloma received alloBMTs using T cell depletion by elutriation.
  • Fifty-three percent (27 of 51) of patients had primary refractory disease at the time of transplantation, 10% (5 of 51) had relapsed disease, and 4% (2 of 51) had refractory relapsed disease.
  • The median age was 49 (range, 32 to 62) years, and the median time from diagnosis to transplantation was 9 (range, 4 to 58) months.
  • Patients had received a median of 1 (range, 1 to 3) regimen and 4 (range, 2 to 16) cycles of chemotherapy.
  • Sixteen patients were given donor lymphocyte infusions (DLI) at the time of relapse (n = 11) or for persistent disease 1 year after transplantation (n = 5).
  • Acute or chronic GVHD was seen in 63% (10 of 16) of patients given DLI.
  • Thus, like chronic myelogenous leukemia, allogeneic T cells appear to have potent antimyeloma activity that is critical for achieving a cure.
  • Unlike chronic myelogenous leukemia, the antimyeloma effect of allogeneic T cells rarely occurs in the absence of clinically significant GVHD.
  • [MeSH-major] Bone Marrow Transplantation / methods. Lymphocyte Depletion. Lymphocyte Transfusion. Multiple Myeloma / therapy
  • [MeSH-minor] Adult. Female. Follow-Up Studies. Graft Survival. Graft vs Host Disease / mortality. Graft vs Host Disease / prevention & control. Humans. Male. Middle Aged. Prognosis. Survival Analysis. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Multiple myeloma.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12766881.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA15396
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


25. Balducci L, Beghe' C: Cancer and age in the USA. Crit Rev Oncol Hematol; 2001 Feb;37(2):137-45
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Specific interactions of cancer and aging include: Increased incidence of cancer with the age: This association may be reported to three factors: duration of carcinogenesis; increased susceptibility of older tissues to late stage carcinogens, and systemic effects of aging, including immune-senescence and enhanced cytokine production.
  • Biological behavior of cancer: With aging, the prognosis of certain neoplasms, including acute myelogenous leukemia and large-cell non-Hodgkin's lymphoma worsens, whereas the behavior of other tumors becomes more indolent.
  • Goals of prevention and treatment: Given the limited life-expectancy of older individuals and reduced tolerance of clinical intervention, the main goal is compression of morbidity, rather than prolongation of survival.
  • Cancer treatment: The risk of surgical complications increases only slightly with age for elective surgery, but increases dramatically for emergency surgery.
  • Radiation therapy appears a valuable method of cancer treatment in patients of all ages.
  • Chemotherapy can be made safer by the following provisions: use of hemopoietic growth factors for patients aged 70 and older receiving moderately toxic chemotherapy (CHOP and CHOP-like); maintenance of hemoglobin levels at 12 g/dl with erythropoietin; adjustment of the dose of renally excreted agents to the glomerular filtration rate; selection of the best candidates for chemotherapy based on comprehensive geriatric assessment.
  • [MeSH-minor] Adult. Age Factors. Aged. Humans. Middle Aged. United States / epidemiology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11166587.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 38
  •  go-up   go-down


26. Sampson M, Archibong AE, Powell A, Strange B, Roberson S, Hills ER, Bourne P: Perturbation of the developmental potential of preimplantation mouse embryos by hydroxyurea. Int J Environ Res Public Health; 2010 05;7(5):2033-44
Hazardous Substances Data Bank. HYDROXYUREA .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fourteen cases of HU therapy in pregnant patients diagnosed with acute or chronic myelogenous leukemia, primary thrombocythemia, or sickle cell disease (SCD) have been reported.
  • Three pregnancies were terminated by elective abortion; 1 woman developed eclampsia and delivered a phenotypically normal stillborn infant.
  • The objective of this study was to assess the risks associated with a clinically relevant dose of HU used for the treatment of SCD, on ovulation rate and embryo development, using adult C57BL/6J female mice as a model.
  • In Experiment 1, adult female mice were randomly assigned to a treatment or a control group (N = 20/group).
  • Treatment consisted of oral HU (30 mg/kg) for 28 days; while control mice received saline (HU vehicle).
  • Ovulation was induced in the remaining mice at 48 hours post PMSG with human chorionic gonadotropin (hCG) and immediately caged with adult males for mating.
  • Fewer embryos retrieved from HU-treated mice developed to blastocyst stage (32%) compared with those from controls (60%; P < 0.05).
  • Furthermore, continuous or intermittent in vitro exposures of embryos to HU also resulted in reduced development to blastocyst stage (continuous HU, 9 vs. control, 63%; P < 0.05; intermittent HU, 20 vs. control, 62%; P < 0.05) with embryos exposed continuously to HU in vitro fairing worse.
  • [MeSH-major] Blastocyst / drug effects. Hydroxyurea / toxicity

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biol Reprod. 1987 May;36(4):890-8 [3109516.001]
  • [Cites] Biol Reprod. 1985 Jun;32(5):1069-79 [3926013.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):8925-8 [7692440.001]
  • [Cites] N Engl J Med. 1995 Apr 27;332(17):1132-6 [7700286.001]
  • [Cites] Genes Dev. 1996 Apr 15;10(8):934-47 [8608941.001]
  • [Cites] N Engl J Med. 1999 Apr 1;340(13):1021-30 [10099145.001]
  • [Cites] Blood. 1999 Sep 1;94(5):1517-36 [10477676.001]
  • [Cites] Exp Toxicol Pathol. 2004 Oct;56(1-2):1-7 [15581269.001]
  • [Cites] Toxicol Sci. 2005 Jun;85(2):1013-23 [15772364.001]
  • [Cites] AIDS Res Hum Retroviruses. 2007 Nov;23(11):1360-5 [18184078.001]
  • [Cites] Int J Environ Res Public Health. 2009 Mar;6(3):1124-44 [19440437.001]
  • [Cites] Ann Hematol. 2009 Oct;88(10):967-71 [19214510.001]
  • [Cites] Environ Res. 2009 Oct;109(7):922-9 [19682677.001]
  • [Cites] Pharmacotherapy. 1999 Dec;19(12):1459-62 [10600098.001]
  • [Cites] Exp Gerontol. 2000 Aug;35(5):553-71 [10978678.001]
  • [Cites] Chemotherapy. 2001 Jul-Aug;47(4):270-8 [11399864.001]
  • [Cites] Reprod Toxicol. 2002 Nov-Dec;16(6):801-8 [12401509.001]
  • [Cites] Endocrinology. 1982 Dec;111(6):2077-86 [6291909.001]
  • [Cites] J Reprod Fertil. 1984 Sep;72(1):39-53 [6540808.001]
  • [Cites] Semin Oncol. 1992 Jun;19(3 Suppl 9):1-10 [1641648.001]
  • (PMID = 20623009.001).
  • [ISSN] 1660-4601
  • [Journal-full-title] International journal of environmental research and public health
  • [ISO-abbreviation] Int J Environ Res Public Health
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / U54 HD044315; United States / NICHD NIH HHS / HD / R01 HD020419-19S1; United States / NICHD NIH HHS / HD / 1U54HD044315; United States / NCRR NIH HHS / RR / G12 RR003032; United States / NCRR NIH HHS / RR / G12RR03032; United States / NICHD NIH HHS / HD / R01 HD020419
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Switzerland
  • [Chemical-registry-number] X6Q56QN5QC / Hydroxyurea
  • [Other-IDs] NLM/ PMC2898034
  • [Keywords] NOTNLM ; 2-cell embryo (major topic) / blastocyst (major topic) / estradiol-17β ovulation rate (major topic) / hydroxyurea (major topic) / ovarian weight (major topic)
  •  go-up   go-down






Advertisement